Liver | Nano Publications

2021 – NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I Trial

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Immune checkpoint inhibitors (ICIs) have led to improved treatment outcomes in a variety of cancers; however, the majority of patients exhibit resistance to ICIs. Overcoming this resistance is a major challenge in immune-oncology. Radiation therapy (RT) has emerged as a promising combination with ICIs since it may act synergistically with ICIs by producing an immunomodulatory effect. […]

Continuer la lecture…

2021 – NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I Trial

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Continuer la lecture…

2019 – ESMO – NBTXR3 activated by SBRT in liver cancers

Abstracts, Donnée clinique de NBTXR3, Foie

Treatment of hepatocellular carcinoma (HCC) and liver metastasis (mets) is challenging due to presence of underlying disease, e.g. cirrhosis. Stereotactic body radiation therapy (SBRT) is a well-tolerated alternative for inoperable patients (pts), yet maximal dose to the tumor is limited by potential toxicity to surrounding healthy tissues. Otherwise inert, NBTXR3 (hafnium oxide nanoparticles) when acti- vated by ionizing radiation (RT) augments dose deposit within tumor cells, increasing tumor cell death compared to RT alone. […]

Continuer la lecture…

2019 – ASCO GI – Phase I/II NBTXR3 in HCC and Liver Metastasis

Abstracts, Donnée clinique de NBTXR3, Foie

Compared to younger individuals, elderly patients with head and neck squamous cell carcinoma (HNSCC) have limited therapeutic options. Despite representing approximately 47% of the affected population with an increasing incidence, older patients are underrepresented from HNSCC prospective clinical trials further limiting their therapeutic options. […]

Continuer la lecture…

2017 – Abstract – 13th Journées cancéropole GSO – HfO2 nanoparticles in solid tumors

Abstracts, Donnée clinique de NBTXR3, Foie, Rectum, STM, Tête & Cou

The enclosed abstract was presented at the 13th Journées cancéropole Grand Sud-Ouest at Poitiers. The abstract Hafnium oxide nanoparticles as an emergent promising treatment for solid tumors describes how hafnium oxide nanoparticles were designed at the nanoscale in the form of crystalline 50nm-particles to efficiently absorb ionizing radiation and increase the radiation dose deposited – “hot spots” of energy deposit – from within the tumor cells for efficient cell killing. […]

Continuer la lecture…

2018 – Multidisciplinary H&N – NBTXR3 for Head and Neck Cancer

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

NBTXR3 administered as a single intratumoral injection and activated by radiotherapy, is currently evaluated in a phase I clinical trial for head and neck cancer. At the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale Arizona, preliminary results were presented by prof. C. Le Tourneau. […]

Continuer la lecture…

2018 – ASCO GI – A phase I/II trial of NBTXR3 nanoparticles activated by SBRT in the treatment of liver cancers

Abstracts, Donnée clinique de NBTXR3, Foie

The physical mode of action of NBTXR3 may represent a breakthrough approach for the local treatment of liver cancers, as it does not engage liver and renal functions, i.e. nanoparticles are not metabolized and not excreted by kidney. A phase I/II trial has been implemented for the treatment of hepatocellular carcinoma and liver metastasis. […]

Continuer la lecture…

2017 – Abstract – 35th CFS – Hafnium Oxide Nanoparticles: An Emergent Promising Treatment for Solid Tumors

Abstracts, In Vitro, In Vitro in Vivo NBTXR3

Hafnium oxide nanoparticles: an emergent promising treatment for solid tumors To improve tumor response, radiotherapy (RT) has been combined with chemical agents, radiosensitizers and monoclonal antibodies. However, the complexity of these associations in terms of pharmacology, local control, clinical outcome benefits or patient quality of life underlines the need for the development of new therapeutic approaches. […]

Continuer la lecture…

2017 – Abstract SITC Conference Maryland – Non Clinical

Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Hafnium oxide, an electron-dense material, was designed at the nanoscale to increase the radiation dose deposited from within the cancer cells: “Hot spot” of energy deposit where the nanoparticles are when exposed to radiation therapy (RT). Preclinical studies have demonstrated increase of cancer cells killing in vitro and marked antitumor efficacy in vivo with presence of these nanoparticles […]

Continuer la lecture…

2017 – Abstract Conference Immunotherapy Radiotherapy Combinations NYC

Abstracts, In Vitro, In Vitro in Vivo NBTXR3, In Vivo

Continuer la lecture…